Popular Articles

New Animal Study Of Rexahn's Serdaxin™ Shows Drug's Promise To Treat Anxiety And Depression With Minimal Side Effects
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), announced the results of a wide-ranging animal study offering more evidence that Serdaxin™ may be an effective therapeutic for the treatment of anxiety disorders in humans. Serdaxin is Rexahn"s leading anxiety and depression drug candidate, and is currently in Phase II clinical trials.
generic viagra online
Lautenberg, Longtime Senate Leader On Anti-Tobacco Efforts, Hails Passage Of Fda Tobacco Bill
Senator Frank R. Lautenberg (D-NJ), a longtime Senate leader in the fight against Big Tobacco, today hailed the historic passage of the FDA tobacco bill. The bill would give the Food and Drug Administration (FDA) the authority to regulate the sale and distribution of tobacco products, and prevent cigarette makers from targeting children in their advertising and marketing and making false claims to the public.
News of the day
Inventors Develop Novel Technique To Help Customize, Enhance The Effectiveness Of Bladder Cancer Treatment
Researchers in the University of Virginia Department of Urology have developed a novel method that could help physicians determine the best course of treatment for patients suffering from bladder cancer.
Diagnostics

IPS Examines How Funding Cuts Might Affect HIV/AIDS Treatment Programs Worldwide

Inter Press Service examines how "[f]ailure to sustain funding for HIV/AIDS treatment programmes could lead to a rising number of deaths, particularly in Africa." Examples cited by the news service include: "The Tanzanian government ò€¦ had to reduce its HIV budget by a quarter, while Swaziland lowered its 2011 treatment coverage target from 60 percent to 50 percent, which will affect about 40,000 HIV-positive people." In Uganda, "some PEPFAR-funded non-governmental organizations" were "instructed to stop enrolment in treatment," and "Malawi is expecting national drug shortages and in the process of putting into place an emergency plan." During the 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention meeting in Cape Town, South Africa, that concluded Wednesday, Eric Goemaere, head of Medecins Sans Frontieres (MSF) in South Africa, spoke about the current gaps in funding for international HIV/AIDS programs, expressing, as described by IPS, that "the threat to HIV funding has less to do with the global financial crisis than with a general lack of commitment from some rich nations, such as France and Italy, who provide 0.4 percent and 0.1 percent of all global HIV/AIDS res, despite the size of their economies." Hoosen Coovadia from the University of KwaZulu-Natal suggested that more money would be available for international HIV/AIDS programs if only "governments were implementing health programmes more efficiently," IPS writes. "We have wasted money by not planning and targeting properly," Coovadia said. "As a result, our services are collapsing. We need real leadership and cost-effective interventions." IPS writes: PEPFAR, "which contributes more than $3.7 billion to HIV prevention and care globally, has not increased its budget this year, despite President Barack Obama"s promise of an annual increase of $1 billion. Another key global donor, the Global Fund to Fight AIDS, Tuberculosis and Malaria, has announced it is facing a budget shortfall of between three and four billion dollars." The article quotes other HIV experts and examines antiretroviral stock-outs and the risk of drug resistance (Palitza, 7/22). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):